Eirini Christodoulou, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| beta-Cyclodextrins | 4 | 2021 | 68 | 0.970 |
Why?
|
| Drug Compounding | 4 | 2021 | 247 | 0.900 |
Why?
|
| Crocus | 3 | 2021 | 9 | 0.880 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2020 | 47 | 0.740 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2020 | 70 | 0.730 |
Why?
|
| Dysplastic Nevus Syndrome | 1 | 2020 | 61 | 0.700 |
Why?
|
| Silymarin | 2 | 2017 | 44 | 0.660 |
Why?
|
| Protein Phosphatase 2 | 1 | 2020 | 236 | 0.630 |
Why?
|
| Loss of Heterozygosity | 1 | 2020 | 665 | 0.600 |
Why?
|
| Gene Knockout Techniques | 1 | 2020 | 789 | 0.580 |
Why?
|
| Melanoma | 3 | 2020 | 5572 | 0.580 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 693 | 0.560 |
Why?
|
| Plant Extracts | 3 | 2021 | 491 | 0.560 |
Why?
|
| Uveal Neoplasms | 1 | 2019 | 333 | 0.550 |
Why?
|
| Cyclodextrins | 3 | 2021 | 63 | 0.550 |
Why?
|
| Pharmaceutical Preparations | 2 | 2021 | 1071 | 0.520 |
Why?
|
| Carotenoids | 1 | 2018 | 618 | 0.520 |
Why?
|
| Drug Delivery Systems | 2 | 2021 | 2200 | 0.420 |
Why?
|
| Freeze Drying | 4 | 2021 | 100 | 0.400 |
Why?
|
| Antioxidants | 2 | 2017 | 1642 | 0.380 |
Why?
|
| Genome, Human | 1 | 2020 | 4359 | 0.290 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2021 | 442 | 0.280 |
Why?
|
| Biological Availability | 2 | 2018 | 394 | 0.270 |
Why?
|
| Molecular Dynamics Simulation | 4 | 2021 | 405 | 0.250 |
Why?
|
| Solubility | 3 | 2021 | 1089 | 0.250 |
Why?
|
| Calorimetry, Differential Scanning | 2 | 2021 | 95 | 0.240 |
Why?
|
| Biphenyl Compounds | 2 | 2019 | 943 | 0.220 |
Why?
|
| Tetrazoles | 2 | 2019 | 861 | 0.210 |
Why?
|
| Lecithins | 1 | 2021 | 17 | 0.200 |
Why?
|
| Biological Products | 2 | 2021 | 885 | 0.190 |
Why?
|
| Leigh Disease | 1 | 2022 | 87 | 0.190 |
Why?
|
| Atherosclerosis | 3 | 2022 | 3416 | 0.180 |
Why?
|
| Reperfusion Injury | 2 | 2017 | 1004 | 0.180 |
Why?
|
| Quercetin | 2 | 2021 | 96 | 0.180 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2022 | 1487 | 0.170 |
Why?
|
| Administration, Oral | 2 | 2018 | 3966 | 0.160 |
Why?
|
| Antihypertensive Agents | 2 | 2020 | 2043 | 0.160 |
Why?
|
| Physical Conditioning, Animal | 1 | 2022 | 361 | 0.160 |
Why?
|
| Mitochondrial Diseases | 1 | 2022 | 333 | 0.150 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2021 | 510 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 17435 | 0.150 |
Why?
|
| Penetrance | 1 | 2019 | 386 | 0.150 |
Why?
|
| Cadherins | 1 | 2022 | 904 | 0.150 |
Why?
|
| 1,2-Dipalmitoylphosphatidylcholine | 1 | 2017 | 41 | 0.150 |
Why?
|
| Random Allocation | 2 | 2018 | 2385 | 0.140 |
Why?
|
| Prodrugs | 1 | 2019 | 259 | 0.140 |
Why?
|
| Protective Agents | 1 | 2017 | 151 | 0.140 |
Why?
|
| Drug Carriers | 1 | 2021 | 694 | 0.130 |
Why?
|
| Flowers | 1 | 2015 | 31 | 0.130 |
Why?
|
| Vitamin A | 1 | 2018 | 609 | 0.130 |
Why?
|
| Hypercholesterolemia | 1 | 2022 | 1146 | 0.130 |
Why?
|
| Plants, Medicinal | 1 | 2015 | 162 | 0.120 |
Why?
|
| Tissue Distribution | 2 | 2017 | 2283 | 0.120 |
Why?
|
| Lipid Bilayers | 1 | 2017 | 380 | 0.120 |
Why?
|
| Benzimidazoles | 1 | 2019 | 857 | 0.110 |
Why?
|
| Phytotherapy | 1 | 2015 | 289 | 0.110 |
Why?
|
| Liposomes | 1 | 2017 | 774 | 0.110 |
Why?
|
| Aortic Diseases | 1 | 2019 | 702 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 6138 | 0.110 |
Why?
|
| Pedigree | 1 | 2019 | 4555 | 0.100 |
Why?
|
| Aorta | 1 | 2019 | 2027 | 0.090 |
Why?
|
| Liver | 3 | 2017 | 7371 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 1853 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 1781 | 0.080 |
Why?
|
| Urocortins | 1 | 2008 | 19 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 21529 | 0.080 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2020 | 258 | 0.080 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2008 | 89 | 0.080 |
Why?
|
| Molecular Conformation | 2 | 2020 | 548 | 0.080 |
Why?
|
| Animals | 9 | 2022 | 166308 | 0.070 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2008 | 360 | 0.070 |
Why?
|
| Thermodynamics | 2 | 2020 | 593 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 1841 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2020 | 10303 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 3269 | 0.060 |
Why?
|
| Rats, Wistar | 2 | 2017 | 1858 | 0.060 |
Why?
|
| Humans | 14 | 2022 | 746070 | 0.050 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2022 | 56 | 0.050 |
Why?
|
| Collagen | 2 | 2022 | 2616 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2022 | 146 | 0.050 |
Why?
|
| Hepatocytes | 1 | 2008 | 1209 | 0.050 |
Why?
|
| Kidney | 1 | 2017 | 6984 | 0.050 |
Why?
|
| Powders | 1 | 2021 | 80 | 0.050 |
Why?
|
| Mannitol | 1 | 2021 | 180 | 0.050 |
Why?
|
| Elastin | 1 | 2022 | 300 | 0.050 |
Why?
|
| X-Ray Diffraction | 1 | 2021 | 418 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 15367 | 0.050 |
Why?
|
| Liver Diseases | 1 | 2008 | 1268 | 0.040 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2021 | 394 | 0.040 |
Why?
|
| Male | 6 | 2022 | 351098 | 0.040 |
Why?
|
| Models, Biological | 1 | 2015 | 9443 | 0.040 |
Why?
|
| Mutation | 2 | 2022 | 29620 | 0.040 |
Why?
|
| Hydrogen Bonding | 1 | 2019 | 292 | 0.040 |
Why?
|
| Rupture, Spontaneous | 1 | 2019 | 348 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2021 | 410 | 0.040 |
Why?
|
| Keratin-18 | 1 | 2017 | 40 | 0.040 |
Why?
|
| Fas Ligand Protein | 1 | 2017 | 212 | 0.040 |
Why?
|
| Phase Transition | 1 | 2017 | 71 | 0.040 |
Why?
|
| DNA, Mitochondrial | 1 | 2022 | 835 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2022 | 1118 | 0.030 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2019 | 683 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2022 | 1418 | 0.030 |
Why?
|
| HMGB1 Protein | 1 | 2017 | 139 | 0.030 |
Why?
|
| Mice | 2 | 2022 | 80065 | 0.030 |
Why?
|
| Rabbits | 1 | 2021 | 4783 | 0.030 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 17831 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 57552 | 0.030 |
Why?
|
| Renin-Angiotensin System | 1 | 2019 | 741 | 0.030 |
Why?
|
| Necrosis | 1 | 2017 | 1593 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 1349 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2022 | 3898 | 0.020 |
Why?
|
| Rats | 2 | 2017 | 23681 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 4858 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2016 | 1957 | 0.020 |
Why?
|
| Aortic Valve Stenosis | 1 | 2022 | 2038 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2019 | 4179 | 0.020 |
Why?
|
| Seizures | 1 | 2022 | 2880 | 0.020 |
Why?
|
| Kinetics | 1 | 2017 | 6354 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 2881 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2022 | 14212 | 0.020 |
Why?
|
| Aged | 1 | 2019 | 164222 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2016 | 5378 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2016 | 3742 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 4335 | 0.020 |
Why?
|
| Middle Aged | 1 | 2019 | 214419 | 0.020 |
Why?
|
| Female | 2 | 2022 | 382129 | 0.010 |
Why?
|
| Disease Progression | 1 | 2019 | 13302 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 16652 | 0.010 |
Why?
|
| Time Factors | 1 | 2019 | 39589 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2019 | 23115 | 0.010 |
Why?
|
| Gene Expression | 1 | 2008 | 7579 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2008 | 4926 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 11037 | 0.010 |
Why?
|
| Brain | 1 | 2021 | 26597 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 12742 | 0.010 |
Why?
|